Pioneering diagnostics
E.g., 10/12/2018
E.g., 10/12/2018
PreviousNext

bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking

13 November, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel and the CE-Mark of the BIOFIRE® FILMARRAY®...

bioMérieux acquires a majority stake in Hybiome and strengthens its presence both in China and in the immunoassay market

09 November, 2018

bioMérieux, a world leader in the field of in vitro diagnostics, today announces the acquisition of a majority holding in Suzhou Hybiome Biomedical Engineering Co.Ltd. This announcement follows the acquisition of a minority stake in July 2018.
 
Founded in...

Business review for the nine months ended September 30, 2018

18 October, 2018

  • Strong sales dynamic confirmed in third quarter, with an 8.8% increase in organic sales
  • Growth of 9.8% at constant exchange rates and scope of consolidation over the nine months ended September 30:
    • €1,749 million in sales
    • Up 4.5% as reported
    ...

bioMérieux commitments in the CDC’s “AMR Challenge”, a joint public-private sector initiative to accelerate the fight against antimicrobial resistance

25 September, 2018

Marcy l’Étoile (France) – Sept. 25, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, is participating in the AMR Challenge, a new Centers for...

First-Half 2018 Results

05 September, 2018

  • Strong sales dynamic, with sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
    • €1,169 million in sales
    • Up 3.1% as reported
  • Contributive operating income before non-...

Second-Quarter 2018 Business Review

18 July, 2018

  • Strong sales dynamic confirmed in second quarter, leading to sales up 10.4% over the first half at constant exchange rates and scope of consolidation:
    • €1,169 million in sales 
    • Up 3.1% as reported
  • ...

NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in Acute Dialysis Quality Initiative Recommendations

12 June, 2018

The biomarkers in the NEPHROCHECK® test, an FDA-cleared and CE-marked urine test that indicates kidney stress in advance of acute kidney injury (...

bioMérieux launches ENDOZYME® II GO, an innovative test for the detection of endotoxins in pharmaceutical microbiology control

31 May, 2018

bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of ENDOZYME® II GO, a new endotoxin test in the bioMérieux ENDONEXTTM range of recombinant horseshoe crab Factor C (rFC) assays. This new...

NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in Groundbreaking Consensus Statement of Best Practices to Enhance Recovery after Heart Surgery

02 May, 2018

Marcy l’Étoile (France) and San Diego (California) - May 2nd, 2018 – The biomarkers in the...

bioMérieux and the University of Antwerp award scholarships to three healthcare professionals for their commitment to improve antibiotic use in order to combat antimicrobial resistance  

23 April, 2018

Marcy l'Étoile (France) – Antwerp (Belgium) – April 23, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, and the Laboratory of Medical Microbiology at the University of Antwerp have awarded three scientific scholarships within the scope of the Global...

PreviousNext